Sepsis is a leading cause of death in children, accounting for 3 million deaths globally each year. Low-middle-income countries, especially India, bear a higher burden of poor outcomes. Almost half of children in septic shock admitted to Paediatric Intensive Care Units (PICUs) in India do not survive. Current treatments for septic shock are limited, highlighting the urgent need for new therapies.
This collaborative project, funded by the Unnati Research Collaboration Grants, provided education in high-quality clinical trial methodology to Indian PICU researchers. The project’s aim was to support Indian hospitals to participate in international clinical trials and enhance their international visibility, ultimately benefitting their sickest children.
The collaboration between The University of Queensland, four Indian teaching hospitals and medical colleges, and The George Institute, India, used the Resuscitation in Paediatric Septic Shock using Mega-Dose Vitamin C and Hydrocortisone (RESPOND) Trial as a case study. The internationally recognised trial aims to evaluate the impact of high doses of vitamin C and hydrocortisone in the treatment of children with septic shock, following promising results in adult trials.